Table 1 Patient characteristics at baseline
|  | All, n = 57 | HORUS, n = 26 | UMC Utrecht, n = 20 | LUMC, n = 11 | p value |
|---|---|---|---|---|---|
Female, n (%) | 41 (72) | 22 (85) | 12 (60) | 7 (64) | 0.151 |
Age in years, mean (SD) | 56.6 (11.2) | 59.3 (10.8) | 56.7 (11.6) | 50.1 (9.5) | 0.072 |
Disease duration in years, median (IQR) | 11.5 (6.3–16.4) | 9.9 (4.1–14.4) | 13.4 (8.4–17.6) | 13.0 (5.2–15.5) | 0.463 |
Smoking status, number (%) | |||||
 No | 37 (65) | 16 (62) | 12 (60) | 9 (82) | 0.421 |
 Yes | 20 (35) | 10 (38) | 8 (40) | 2 (18) | |
RF positive, number (%) | 51 (90) | 23 (89) | 19 (95) | 9 (82) | 0.511 |
ACPA positive, number (%) | 44 (80) | 19 (79), n = 24 | 17 (85) | 8 (73) | 0.711 |
Menopausal status, females (%) | |||||
 Pre-menopausal | 14 (25) | 6 (23) | 5 (25) | 3 (27) | 0.301 |
 Post-menopausal | 27 (47) | 16 (62) | 7 (35) | 4 (36) | |
SJC28, median (IQR) | 9 (4–16) | 9 (4–15) | 12 (8–19), n = 19 | 4 (1–10), n = 8 | 0.023 |
TJC28, median (IQR) | 15 (10–23) | 16 (11–25) | 14 (8–17), n = 19 | 13 (5–24), n = 8 | 0.353 |
VAS-GH, 0–100 mm (worst), median (IQR) | 64 (45–73) | 69 (40–78) | 57 (46–69), n = 19 | 65 (53–84), n = 8 | 0.363 |
ESR, mm/h, median (IQR) | 37 (21–51) | 32 (12–41), n = 24 | 52 (21–91), n = 18 | 32 (29–44), n = 7 | 0.023 |
CRP, mg/L, median (IQR) | 15 (6–34) | 11 (5–25), n = 25 | 29 (11–50), n = 18 | 13 (5–56), n = 5 | 0.023 |
hsCRP, mg/L, median (IQR) | NA | 10 (3–26) | NA | NA | NA |
DAS28-ESR, median (IQR) | 6.3 (5.4–7.1) | 6.2 (5.0–7.2), n = 25 | 6.6 (5.8–7.1), n = 18 | 6.1 (3.8–7.3), n = 8 | 0.643 |
DAS28-hsCRP, median (IQR) | NA | 5.8 (4.6–6.8) | NA | NA | NA |
MBDA score, median (IQR) | 54 (44–70) | 51 (44–67), n = 25 | 64 (49–74) | 55 (34–71), n = 7 | 0.153 |
HAQ, median (IQR) | 1.8 (1.4–2.1) | 1.9 (1.7–2.1) | 1.5 (1.1–1.9), n = 11 | 1.3 (1.3–1.9), n = 7 | 0.023 |
SHS, median (IQR) | 44 (24–128) | NA | 61 (29–142), n = 19 | 25 (21–94), n = 8 | 0.343 |